‘It’s a thorny issue.’ Why a fight over DNA data imperils a global conservation pact
By Erik Stokstad,
Science
| 04. 05. 2022
For conservation biologists, the highest item on the global agenda this year is persuading the world’s nations to agree on new targets for saving nature. National leaders are scheduled to meet in China later this year to finalize a new strategic plan for the Convention on Biological Diversity (CBD), a 30-year-old global pact that sets decadal goals for preserving species and ecosystems. Last week, however, negotiators in Geneva reached an impasse. A major stumbling block is how the world should share billions of bits of genetic data stored on computers around the world.
The debate over these data—known as digital sequence information (DSI)—is new, but it echoes a long-standing point of contention. Developing nations that are rich in biodiversity, such as those in the tropics, have argued that more developed nations have exploited their natural heritage for commercial gain—for example, by using plants collected in the tropics to develop new crops or drugs—without sharing any of the revenue or benefits. That irks many parties, because a main objective of the CBD is to use the conservation of biodiversity to promote...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...